Last reviewed · How we verify
NCT03604237
Targeted Forceps Biopsy for Colorectal Tumors
NA trial testing Targeted group in Colorectal Neoplasms in 64 participants. Status unknown.
1 August 2018
Quick facts
| Lead sponsor | Kyungpook National University Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | diagnostic |
| Enrollment | 64 |
| Start date | 1 September 2017 |
| Primary completion | 1 August 2018 |
| Estimated completion | 1 October 2018 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Targeted group
Conditions studied
- Colorectal Neoplasms — all drugs for Colorectal Neoplasms →
Sponsor
Kyungpook National University Hospital
Who can join
Adults 19 to 85, any sex, with Colorectal Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates whether targeted forceps biopsy with careful tumor surface evaluation can improve diagnostic accuracy of colorectal tumors larger than 2 cm during colonoscopy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03604237
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Neoplasms
Currently open trials in the same condition.
- NCT06983639 — Randomized Trial Comparing Fecal Testing (FIT) to Colonoscopy for Post-polypectomy Surveillance · NA · recruiting
- NCT07222800 — Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult · Phase 3 · recruiting
- NCT07239479 — DEXDES Trial: Dexmedetomidine-Desflurane Combination in Laparoscopic Colectomy · NA · recruiting
- NCT07262840 — Health Behavior Change in High-Risk Colorectal Cancer Individuals · NA · recruiting
- NCT07257653 — The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line · Phase 2 · recruiting
Other Kyungpook National University Hospital trials
Trials by the same sponsor.
- NCT07265817 — Fecal Microbiota Transplantation for Decolonization of Multidrug-resistant Microorganisms · NA · not yet recruiting
- NCT06215040 — The Treatment Effect for Asymptomatic Common Bile Duct Stone · recruiting
- NCT05849324 — Intravascular Injection Rate During Lumbar Transforaminal Epidural Block Using Bent or Straight Needles · NA · unknown
- NCT05083026 — Neutralizing Antibody Level After COVID-19 Vaccination · unknown
- NCT05046054 — The Effect of Transcutaneous Electrical Nerve Stimulation on Pain During Propofol Injection · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03604237 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kyungpook National University Hospital
- Last refreshed: 27 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03604237.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing